Liver Resection After Selective Internal Radiation Therapy with Yttrium-90: Safety and Outcomes

[1]  M. Abecassis,et al.  Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. , 2018, Journal of vascular and interventional radiology : JVIR.

[2]  D. Tiniakos,et al.  Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection , 2018, CardioVascular and Interventional Radiology.

[3]  V. Gebski,et al.  First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials , 2017, The Lancet. Oncology.

[4]  P. Gibbs,et al.  REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± RadioEmbolization (SIRT) in the randomized SIRFLOX trial. , 2017 .

[5]  M. G. Doherty,et al.  Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis , 2017, Annals of Surgical Oncology.

[6]  C. Karapetis,et al.  Selective internal radiation therapy for liver metastases from colorectal cancer. , 2016, Cancer treatment reviews.

[7]  V. Gebski,et al.  SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Golfieri,et al.  Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies , 2016, Liver Cancer.

[9]  P. Song,et al.  An updated systematic review of the evolution of ALPPS and evaluation of its advantages and disadvantages in accordance with current evidence , 2016, Medicine.

[10]  Xin Zhao,et al.  Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. , 2015, Bioscience trends.

[11]  K. Tatsch,et al.  Liver resection after selective internal radiotherapy (SIRT): Proof of concept, initial survival, and safety , 2015, Journal of surgical oncology.

[12]  P. Pockros,et al.  Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. , 2015, Journal of gastrointestinal oncology.

[13]  L. Henry,et al.  Liver Resection for Metastatic Disease After Y90 Radioembolization: A Case Series with Long-Term Follow-Up , 2015, Annals of Surgical Oncology.

[14]  P. Chow,et al.  Yttrium-90 Microspheres: A Review of Its Emerging Clinical Indications , 2014, Liver Cancer.

[15]  F. Rotellar,et al.  The safety of resection post-selective internal radiation therapy. , 2014, Future Oncology.

[16]  C. Bruns,et al.  The evidence for resection post-selective internal radiation therapy. , 2014, Future oncology.

[17]  D. Manas.  Hypertrophy in the contralateral lobe post-selective internal radiation therapy. , 2014, Future Oncology.

[18]  G. Chatellier,et al.  Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial , 2014, Trials.

[19]  V. Gebski,et al.  Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study , 2014, BMC Cancer.

[20]  D. Sze,et al.  The Efficacy of Hepatic 90Y Resin Radioembolization for Metastatic Neuroendocrine Tumors: A Meta-Analysis , 2014, The Journal of Nuclear Medicine.

[21]  C. Justinger,et al.  Intrahepatic cholangiocarcinoma in a transplant liver - selective internal radiation therapy followed by right hemihepatectomy: report of a case , 2014, World Journal of Surgical Oncology.

[22]  A. Kennedy.  Radioembolization of hepatic tumors. , 2014, Journal of gastrointestinal oncology.

[23]  H. Amthauer,et al.  Left‐liver hypertrophy after therapeutic right‐liver radioembolization is substantial but less than after portal vein embolization , 2014, Hepatology.

[24]  H. Wasan,et al.  Safety of Redo Hepatectomy for Colorectal Liver Metastases after Selective Interarterial Radiation Therapy: A Case Report , 2014, Case Reports in Surgery.

[25]  B. Sangro,et al.  Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[26]  Ricky A. Sharma,et al.  Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases , 2012, Journal of Clinical Pathology.

[27]  T. Chua,et al.  Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. , 2010, Anticancer research.

[28]  H. Baba,et al.  Serum HGF and TGF‐β1 levels after right portal vein embolization , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  B. Sangro,et al.  Liver disease induced by radioembolization of liver tumors , 2008, Cancer.

[30]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[31]  M. Reiser,et al.  Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres , 2008, Digestive Diseases and Sciences.

[32]  P. Gibbs,et al.  Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Makuuchi,et al.  Expression of Transforming Growth Factor-α and -β in Hepatic Lobes After Hemihepatic Portal Vein Embolization , 2006, Digestive Diseases and Sciences.

[34]  C. Nutting,et al.  Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. , 2004, International journal of radiation oncology, biology, physics.

[35]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[36]  J. Wong,et al.  Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma , 2003, The British journal of surgery.

[37]  K. Naruse,et al.  Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: clinical and experimental studies. , 2002, Journal of hepatology.

[38]  S. Choo,et al.  A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. , 2015, HPB.

[39]  M. Makuuchi,et al.  Expression of transforming growth factor-alpha and -beta in hepatic lobes after hemihepatic portal vein embolization. , 2006, Digestive diseases and sciences.

[40]  D. C. Henckel,et al.  Case report. , 1995, Journal.